Evidence map›Paper›PMID 34079630›Full record

ArticleAmerican journal of blood research2021

Cutaneous methotrexate-related T-cell lymphoproliferative disorder with CD4, CD30, CD56, EBV-positive tumor cell infiltration: a case illustration and a brief review.

Issei Omori, Ruriko Kawanabe, Yuki Hashimoto, Aya Mitsui, Kako Kodama, Shinichi Nogi, Hirotaka Tsuno, Ayako Horita, Ikuo Saito, Hanako Ohmatsu

Open access · greenAbstract readCase Reports
PubMed Full text at PMC
In one paragraph

Article in American journal of blood research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. CD56 on immune and tumor cells: what is known and beyond?Clinical and experimental immunology · 2025
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Issei OmoriDepartment of Dermatology, National Hospital Organization Sagamihara National Hospital Sagamihara, Kanagawa, Japan.
Ruriko KawanabeDepartment of Dermatology, National Hospital Organization Sagamihara National Hospital Sagamihara, Kanagawa, Japan.
Yuki HashimotoDepartment of Dermatology, National Hospital Organization Sagamihara National Hospital Sagamihara, Kanagawa, Japan.
Aya MitsuiDepartment of Dermatology, National Hospital Organization Sagamihara National Hospital Sagamihara, Kanagawa, Japan.
Kako KodamaDepartment of Rheumatology, National Hospital Organization Sagamihara National Hospital Sagamihara, Kanagawa, Japan.
Shinichi NogiDepartment of Rheumatology, National Hospital Organization Sagamihara National Hospital Sagamihara, Kanagawa, Japan.
Hirotaka TsunoDepartment of Rheumatology, National Hospital Organization Sagamihara National Hospital Sagamihara, Kanagawa, Japan.
Ayako HoritaDepartment of Diagnostic Pathology, National Hospital Organization Sagamihara National Hospital Sagamihara, Kanagawa, Japan.
Ikuo SaitoDepartment of Diagnostic Pathology, National Hospital Organization Sagamihara National Hospital Sagamihara, Kanagawa, Japan.
Hanako OhmatsuDepartment of Dermatology, National Hospital Organization Sagamihara National Hospital Sagamihara, Kanagawa, Japan.
National Sagamihara Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Methotrexate (MTX) is a commonly used anti-metabolite agent. Long-term MTX treatment can cause MTX-related lymphoproliferative disorder (MTX-LPD). T-cell LPDs comprise a small fraction of MTX-LPDs. Epstein-Barr virus (EBV)

Indexed as

lymphoproliferative disorderMethotrexatemethotrexate-related T-cell lymphoproliferative disorder

Identifiers

PMID34079630
PMCPMC8165712
OpenAlexW3164248787

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.